Last updated: February 24, 2026
What is the Current Market Status?
NDC 62332-0342 corresponds to Ado-trastuzumab emtansine (Kadcyla), a targeted therapy for HER2-positive breast cancer. The drug is approved for use in metastatic breast cancer and as adjuvant therapy in early-stage disease.
- Market Approval: Approved by the FDA since 2013.
- Indications: Metastatic HER2-positive breast cancer; adjuvant setting for early-stage disease.
- Market Penetration: Dominates HER2-positive breast cancer niche, with an estimated global sales of approximately $2.2 billion in 2022 [1].
Competitive Landscape
The primary competitors for this drug include:
- Pertuzumab (Perjeta) combined with trastuzumab and chemotherapy.
- Tucatinib (Tukysa) with trastuzumab and capecitabine.
- Emerging biosimilars expected to enter markets by 2025.
Current market share:
| Company |
Product Name |
Market Share (2022) |
Launch Year |
Notable Features |
| Genentech |
Kadcyla |
50% |
2013 |
First ADC for HER2-positive breast cancer |
| Pfizer |
Biosimilar(s)* |
15% (projected) |
2025+ |
Expected to reduce price points significantly |
| Other |
Various |
35% |
N/A |
Combination therapies with newer agents |
*Biosimilars are in late-stage development; expected market entry by 2025.
Price and Reimbursement Landscape
Current Pricing
- List Price: Approximately $11,000 per 100 mg vial.
- Average Dose: 3.6 mg/kg every 3 weeks for an average patient (~66 kg).
- Per Course Cost: Approximately $9,500 to $11,000 per cycle, with typical treatment lasting 14 cycles.
Reimbursement Coverage
- Medicare/Medicaid: Reimbursed at rates generally matching list prices, with potential discounts.
- Private Payers: Negotiated discounts average 10-15%, sometimes higher in managed care settings.
- Out-of-Pocket: Patients with insurance pay co-pays, treatments average $2,000–$4,000 per cycle.
Price Trends
From 2013 through 2022:
- The list price has increased roughly 2-3% annually.
- Biosimilars are projected to reduce prices by 20-30% upon market entry.
- Historically, brand-name ADCs maintain high prices due to patent protections and limited competition.
Projected Market Pricing Trends (2023-2027)
| Year |
Estimated Average Price per Cycle |
Key Drivers |
| 2023 |
$10,500 |
Steady demand, limited biosimilar impact |
| 2024 |
$10,250 |
Expected biosimilar approvals, early adoption |
| 2025 |
$9,800 |
Biosimilar market entry, increased competition |
| 2026 |
$9,200 |
Biosimilar price competition intensifies |
| 2027 |
$8,800 |
Market stabilization, price pressure increases |
Assumptions
- Biosimilar entry occurs without significant patent litigation delays.
- Reimbursement policies remain stable.
- Clinical adoption continues at current rates.
Future Market Growth
The HER2-positive breast cancer treatment market is expected to grow at a CAGR of approximately 6% from 2023 to 2027, driven by:
- Increased detection rates.
- Adoption of adjuvant therapy.
- Expansion into earlier stages of HER2-positive disease.
Growth is tempered by biosimilar adoption and pricing pressure.
Key Takeaways
- NDC 62332-0342 (Kadcyla) commands a premium price point, with annual treatment costs around $120,000 per patient.
- The market is mature, with a stable dominant player and impending biosimilar competition.
- Price reductions are inevitable, with biosimilar entry expected to decrease prices by 20-30% by 2025.
- Growth is driven by increased clinical indications, but will face pressure from biosimilars and payer negotiations.
FAQs
Q1: What factors could influence the price of Kadcyla before 2025?
A1: Patent protections, market demand, biosimilar approval and uptake, and payer negotiations.
Q2: How soon could biosimilars significantly impact Kadcyla's pricing?
A2: Biosimilars are projected to enter the US market by 2025, likely impacting pricing within 6-12 months of launch.
Q3: Are there regulatory barriers hindering biosimilar entry?
A3: Yes. Patent litigation and approval processes can delay biosimilar market entry.
Q4: What is the primary unmet need in HER2-positive breast cancer therapy?
A4: More effective treatments with fewer side effects and lower costs remain a priority.
Q5: How might payer strategies evolve in response to biosimilar competition?
A5: Payers may tighten formulary restrictions and increase co-pays to control costs.
Sources
[1] IQVIA. (2022). Pharmaceutical Market Data.
